MetaCap

Kyverna Therapeutics (KYTX) vs X4 Pharmaceuticals (XFOR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

X4 Pharmaceuticals (XFOR) has outperformed Kyverna Therapeutics (KYTX) over the past year, losing 20.0% versus a loss of 39.9%. X4 Pharmaceuticals is the larger company by market cap ($306.3 million vs $269.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KYTX-39.92%XFOR-20.00%
+64%+9%-45%
Nov 21, 20251 yearNov 20, 2026
KYTX-85.85%XFOR-89.48%
+61%-21%-102%
Feb 5, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KYTX versus XFOR key metrics
MetricKYTXXFOR
Share price$4.26$3.00
Market cap$269.33M$306.34M
1-day change-2.52%+1.35%
YTD return-54.68%-25.00%
1-year return-39.92%-20.00%
5-year return—-97.79%
P/E ratio (TTM)—5.45
EPS (TTM)$-2.75$0.55
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$6.50M
Revenue growth (YoY)—+150.00%
Net income (latest FY)$-161.31M$-79.20M
Gross margin—11.43%
Operating margin—-1336.66%
Net margin—-1218.45%
52-week high$13.67$4.83
52-week low$4.18$2.43
Distance from 52-week high-68.84%-37.89%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+613.62%+286.67%
Average volume867.28K877.70K
Shares outstanding63.22M102.11M
Employees17245
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • XFOR has outperformed KYTX by 19.9 percentage points over the past year.

About Kyverna Therapeutics

KYTX stock →

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 172 employees

About X4 Pharmaceuticals

XFOR stock →

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees

KYTX vs XFOR FAQ

Which is bigger, Kyverna Therapeutics or X4 Pharmaceuticals?

X4 Pharmaceuticals (XFOR) is larger, with a market capitalization of $306.34M compared with $269.33M for Kyverna Therapeutics (KYTX).

Which stock has performed better over the past year, KYTX or XFOR?

XFOR returned -20.00% over the past 12 months, compared with -39.92% for KYTX (price return, excluding dividends). Past performance does not predict future results.

Are Kyverna Therapeutics and X4 Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons